COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition.
Alliances with CVS Health and Javara further embed clinical research into the community healthcare setting, expanding access to patient populations across the U.S to increase diversity in clinical trials
Amarex Clinical Research guides its client to phase II of FDA trials
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
He was previously working as the CEO of IVD business at Trivitron Healthcare and drove its growth through innovation
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Subscribe To Our Newsletter & Stay Updated
